BACKGROUND: : The authors hypothesized that low doses of the hypomethylating agent 5-azacitidine may maximize the graft-versus-leukemia effect and may be tolerated well after allogeneic transplantation (HSCT). METHODS: : The drug was given to 17 patients with acute leukemia as salvage for disease recurrence after HSCT (n = 9 patients) or as maintenance therapy (n = 8 patients). 5-Azacitidine was given subcutaneously daily for 5 days and was repeated every 4 weeks at doses of 16 mg/m(2) (n = 4 patients), 24 mg/m(2) (n = 9 patients), and 40 mg/m(2) (n = 4 patients). A median of 8 cycles was delivered. The median follow-up was 16 months and 11 months after HSCT and 5-azacitidine treatment, respectively. RESULTS: : Five of 9 patients with recurrent disease responded. Four of 13 responding patients developed disease recurrence while they were receiving 5-azacitidine after a median of 10 months. The actuarial 1-year event-free and overall survival rates were 55% and 90%, respectively. There were no extramedullary toxicities, and no graft-versus-host disease exacerbation was observed. CONCLUSIONS: : Low-dose 5-azacitidine may induce durable remissions for patients who develop disease recurrence after HSCT. Further follow-up and a larger group of patients will be necessary to confirm these observations. Cancer 2009. (c) 2009 American Cancer Society.
BACKGROUND: : The authors hypothesized that low doses of the hypomethylating agent 5-azacitidine may maximize the graft-versus-leukemia effect and may be tolerated well after allogeneic transplantation (HSCT). METHODS: : The drug was given to 17 patients with acute leukemia as salvage for disease recurrence after HSCT (n = 9 patients) or as maintenance therapy (n = 8 patients). 5-Azacitidine was given subcutaneously daily for 5 days and was repeated every 4 weeks at doses of 16 mg/m(2) (n = 4 patients), 24 mg/m(2) (n = 9 patients), and 40 mg/m(2) (n = 4 patients). A median of 8 cycles was delivered. The median follow-up was 16 months and 11 months after HSCT and 5-azacitidine treatment, respectively. RESULTS: : Five of 9 patients with recurrent disease responded. Four of 13 responding patients developed disease recurrence while they were receiving 5-azacitidine after a median of 10 months. The actuarial 1-year event-free and overall survival rates were 55% and 90%, respectively. There were no extramedullary toxicities, and no graft-versus-host disease exacerbation was observed. CONCLUSIONS: : Low-dose 5-azacitidine may induce durable remissions for patients who develop disease recurrence after HSCT. Further follow-up and a larger group of patients will be necessary to confirm these observations. Cancer 2009. (c) 2009 American Cancer Society.
Authors: F J Giles; J E Cortes; S D Baker; D A Thomas; S O'Brien; T L Smith; M Beran; C Bivins; J Jolivet; H M Kantarjian Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: M Eapen; S A Giralt; M M Horowitz; J P Klein; J E Wagner; M-J Zhang; M S Tallman; D I Marks; B M Camitta; R E Champlin; O Ringdén; C N Bredeson; R Martino; R P Gale; M S Cairo; M R Litzow; M deLima Journal: Bone Marrow Transplant Date: 2004-10 Impact factor: 5.483
Authors: Marcos de Lima; Daniel Couriel; Peter F Thall; Xuemei Wang; Timothy Madden; Roy Jones; Elizabeth J Shpall; Munir Shahjahan; Betty Pierre; Sergio Giralt; Martin Korbling; James A Russell; Richard E Champlin; Borje S Andersson Journal: Blood Date: 2004-04-08 Impact factor: 22.113
Authors: Erica D Warlick; Marcie Tomblyn; Qing Cao; Todd Defor; Bruce R Blazar; Margaret Macmillan; Michael Verneris; John Wagner; Kathryn Dusenbery; Mukta Aurora; Veronika Bachanova; Claudio Brunstein; Linda Burns; Sarah Cooley; Dan Kaufman; Navneet S Majhail; Brian McClune; Philip McGlave; Jeffrey Miller; Betul Oran; Arne Slungaard; Gregory Vercellotti; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2010-11-01 Impact factor: 5.742
Authors: Matthew L Cooper; Jaebok Choi; Darja Karpova; Kiran Vij; Julie Ritchey; Mark A Schroeder; John F DiPersio Journal: J Immunol Date: 2017-03-22 Impact factor: 5.422
Authors: Andrew C Harris; Carrie L Kitko; Daniel R Couriel; Thomas M Braun; Sung W Choi; John Magenau; Shin Mineishi; Attaphol Pawarode; Gregory Yanik; John E Levine Journal: Haematologica Date: 2012-10-12 Impact factor: 9.941